Connection

Co-Authors

This is a "connection" page, showing publications co-authored by ANTHONY LUCCI and SARAH MARIE DESNYDER.
Connection Strength

4.413
  1. American Society of Breast Surgeons' Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation. Ann Surg Oncol. 2018 Oct; 25(10):2965-2974.
    View in: PubMed
    Score: 0.670
  2. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast?Cancer. Clin Breast Cancer. 2018 02; 18(1):e73-e77.
    View in: PubMed
    Score: 0.625
  3. Assessment of Practice Patterns Following Publication of the SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Therapy in Stage I and II Invasive Breast Cancer. Ann Surg Oncol. 2015 Oct; 22(10):3250-6.
    View in: PubMed
    Score: 0.546
  4. Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: a survey of the American Society of Breast Surgeons. Ann Surg Oncol. 2012 Oct; 19(10):3152-8.
    View in: PubMed
    Score: 0.222
  5. Invasive lobular carcinoma predicts micrometastasis in breast cancer. J Surg Res. 2012 Sep; 177(1):93-6.
    View in: PubMed
    Score: 0.217
  6. Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Dec; 28(13):8610-8621.
    View in: PubMed
    Score: 0.205
  7. Oncoplastics: techniques for reconstruction of partial breast defects based on tumor location. J Surg Oncol. 2011 Mar 15; 103(4):341-7.
    View in: PubMed
    Score: 0.202
  8. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Aug; 28(8):4265-4274.
    View in: PubMed
    Score: 0.199
  9. The suture scaffold technique for improved cosmesis in partial mastectomy defects. J Surg Oncol. 2010 Aug 01; 102(2):184-6.
    View in: PubMed
    Score: 0.193
  10. Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery? Ann Surg Oncol. 2020 Nov; 27(12):4603-4612.
    View in: PubMed
    Score: 0.193
  11. Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. Ann Surg Oncol. 2017 Oct; 24(10):2981-2988.
    View in: PubMed
    Score: 0.157
  12. Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. Am J Surg. 2017 Oct; 214(4):666-671.
    View in: PubMed
    Score: 0.156
  13. Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients. J Am Coll Surg. 2016 07; 223(1):20-9.
    View in: PubMed
    Score: 0.142
  14. Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.138
  15. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013 Dec; 20(13):4103-12.
    View in: PubMed
    Score: 0.060
  16. American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012 Oct; 19(10):3144-51.
    View in: PubMed
    Score: 0.055
  17. Lymphedema in Inflammatory Breast Cancer Patients Following Trimodal Treatment. Ann Surg Oncol. 2022 Oct; 29(10):6370-6378.
    View in: PubMed
    Score: 0.055
  18. Inflammatory Breast Cancer at the Extremes of Age. Ann Surg Oncol. 2021 Oct; 28(10):5626-5634.
    View in: PubMed
    Score: 0.052
  19. Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. Pract Radiat Oncol. 2019 Nov; 9(6):402-409.
    View in: PubMed
    Score: 0.044
  20. Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg. 2019 01; 269(1):150-157.
    View in: PubMed
    Score: 0.043
  21. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213.
    View in: PubMed
    Score: 0.042
  22. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
    View in: PubMed
    Score: 0.041
  23. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018; 9(8):1437-1447.
    View in: PubMed
    Score: 0.041
  24. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670.
    View in: PubMed
    Score: 0.039
  25. Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol. 2017 04; 18(4):e228-e232.
    View in: PubMed
    Score: 0.038
  26. Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. Ann Surg Oncol. 2016 10; 23(10):3190-8.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.